{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"title":"Mantle-cell lymphoma"},{"categories":[{"measurements":[{"groupId":"OG000","value":"40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"title":"Other low-grade B-cell tumors"}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"description":"Percentage of participants alive without disease relapse.","groups":[{"description":"Rituximab (R) and high-dose cyclophosphamide (HiCy) with pegfilgrastim support.\n\nPegfilgrastim: 6 mg SQ 24-48 hours after last dose of cyclophosphamide.\n\nRituximab: 375 mg/m\\^2/day on Days 1, 4, 8, 11, 45, and 52.\n\nCyclophosphamide: 50 mg/kg/day on Days 15, 16, 17, and 18.","id":"OG000","title":"R-HiCy"}],"paramType":"NUMBER","populationDescription":"Participants were split into two populations for this outcome only: mantle-cell lymphoma and other low-grade B-cell tumors.","reportingStatus":"POSTED","timeFrame":"5 years","title":"Event-free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}